Is Nidan Laborator. overvalued or undervalued?

As of 7 November 2025, Nidan Laborator. has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43, which indicate a moderate valuation compared to its peers.
In comparison to its industry peers, Nidan Laborator. stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 65.65, and also lower than Narayana Hrudaya at 46.53. Despite the fair valuation, the company's return performance has been underwhelming, with a year-to-date decline of 27.56% compared to a 7.81% increase in the Sensex, suggesting potential concerns about its market position and growth prospects.